Introduction: In individuals with type 2 diabetes mellitus, sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure and serious adverse renal events, both in randomized controlled trials and observational studies. Areas covered: In this paper, the authors critically discuss the rationale, results, and implications of the recent placebo-controlled EMPEROR-Reduced trial [NCT03057977], which evaluated empagliflozin in subjects with chronic heart failure and a reduced ejection fraction (HFrEF), with or without diabetes. A parallel with the DAPA-HF trial, investigating dapagliflozin in a similar albeit not fully overlapping population, is also provided. The authors finally provide the reader with their expert perspectives. Expert opinion: EMPEROR-Reduced confirmed and extended the findings from DAPA-HF, especially on renal outcomes, thus strengthening the rationale for considering SGLT2 inhibitors among established treatments in HFrEF. Forthcoming guidelines supported by the knowledge of the clinical pharmacology of SGLT2 inhibitors will hopefully assist cardiologists, nephrologists, and general practitioners in selecting the target population and promoting safe prescribing.

SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR? / Raschi E.; Fadini G.P.; Diemberger I.; Poluzzi E.; De Ponti F.. - In: EXPERT OPINION ON PHARMACOTHERAPY. - ISSN 1465-6566. - ELETTRONICO. - 22:5(2021), pp. 647-650. [10.1080/14656566.2020.1846719]

SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR?

Raschi E.
Primo
;
Diemberger I.;Poluzzi E.;De Ponti F.
2021

Abstract

Introduction: In individuals with type 2 diabetes mellitus, sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure and serious adverse renal events, both in randomized controlled trials and observational studies. Areas covered: In this paper, the authors critically discuss the rationale, results, and implications of the recent placebo-controlled EMPEROR-Reduced trial [NCT03057977], which evaluated empagliflozin in subjects with chronic heart failure and a reduced ejection fraction (HFrEF), with or without diabetes. A parallel with the DAPA-HF trial, investigating dapagliflozin in a similar albeit not fully overlapping population, is also provided. The authors finally provide the reader with their expert perspectives. Expert opinion: EMPEROR-Reduced confirmed and extended the findings from DAPA-HF, especially on renal outcomes, thus strengthening the rationale for considering SGLT2 inhibitors among established treatments in HFrEF. Forthcoming guidelines supported by the knowledge of the clinical pharmacology of SGLT2 inhibitors will hopefully assist cardiologists, nephrologists, and general practitioners in selecting the target population and promoting safe prescribing.
2021
SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR? / Raschi E.; Fadini G.P.; Diemberger I.; Poluzzi E.; De Ponti F.. - In: EXPERT OPINION ON PHARMACOTHERAPY. - ISSN 1465-6566. - ELETTRONICO. - 22:5(2021), pp. 647-650. [10.1080/14656566.2020.1846719]
Raschi E.; Fadini G.P.; Diemberger I.; Poluzzi E.; De Ponti F.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/801727
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact